Bavarian Nordic Secures Contract for 440,000 Smallpox Vaccines
![Bavarian Nordic Secures Contract for 440,000 Smallpox Vaccines](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Bavarian Nordic Receives Contract for Smallpox and Mpox Vaccines
Bavarian Nordic A/S (OMX: BAVA) has announced the award of a contract for 440,000 doses of its MVA-BN smallpox/mpox vaccine to an undisclosed European country. This order was anticipated as part of the 2024 guidance and does not impact the company’s remaining 2024/25 capacity for these vaccines.
CEO's Statement on Strategic Partnerships
Paul Chaplin, President & CEO of Bavarian Nordic, stated that since the last mpox outbreak, the company has formed strategic partnerships with various authorities that acknowledge the urgency to enhance preparedness against smallpox and mpox. This recent order aligns with their original guidance and allows Bavarian Nordic to maintain its capacity to provide up to 10 million doses of their smallpox and mpox vaccine by the end of the following year, with 2 million doses available this year.
Delivery Schedule and Revenue Impact
All vaccines under this contract will be delivered in 2024. This agreement elevates the total value of secured contracts in the Public Preparedness business to nearly DKK 3,000 million, confirming Bavarian Nordic's new guidance at the upper revenue range for 2024, with anticipated total revenue of approximately DKK 5,300 million and EBITDA of approximately DKK 1,350 million. This revenue comprises DKK 3,000 million from Public Preparedness, DKK 2,100 million from Travel Health, and DKK 200 million from contract work.
About MVA-BN Vaccine
MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic), marketed under the brand names JYNNEOS, IMVANEX, and IMVAMUNE, is a non-replicating smallpox and mpox vaccine. It is approved by multiple global health authorities and has received emergency use authorization in several territories for the mpox outbreak. Originally developed with the U.S. government, the vaccine ensures a supply for the entire population, including individuals who cannot receive traditional vaccines.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company dedicated to saving lives through innovative vaccines. As a global leader in smallpox and mpox vaccines, Bavarian Nordic provides crucial support to governments to enhance public health preparedness and boasts a substantial portfolio for travelers and endemic diseases.
Contact Information
For further inquiries, please contact:
Europe: Rolf Sass Sørensen, VP Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Frequently Asked Questions
What is the recent contract Bavarian Nordic announced?
Bavarian Nordic announced a contract for 440,000 doses of their smallpox/mpox vaccine to an undisclosed European country.
How will this contract impact Bavarian Nordic's production capacity?
The contract will not impact the company's remaining production capacity for 2024/25, allowing them to continue to support governments.
What is the total estimated revenue for Bavarian Nordic in 2024?
The estimated total revenue for Bavarian Nordic in 2024 is approximately DKK 5,300 million.
What are the brand names under which MVA-BN is marketed?
MVA-BN is marketed under the brand names JYNNEOS, IMVANEX, and IMVAMUNE.
Who can receive the MVA-BN vaccine?
The vaccine is suitable for the entire population, including immunocompromised individuals who are advised against traditional smallpox vaccines.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Bion Environmental Technologies Secures $500,000 Financing
- Bright Green Partners with Benuvia for Raw Material Supply
- Growth Insights for Global Pharma Grade Plastic Packaging Market
- Veterinary Vaccines Market Growth Insights and Trends
- High-Performance Computing Market Growth to USD 92.33 Billion
- Cancer Vaccines Market Growth Forecast and Insights
- Performance Coatings Market Growth Opportunities
- Industrial Robotics Market Growth Projections for 2032
- Significant Growth Ahead for Blood Culture Tests Market
- CytoDyn Partners with CRO for Phase II Inflammation Study